Oxford BioDynamics (OBD) Competitors

Futura Medical (LON:FUM) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Is FUM or OBD more profitable?

Futura Medical has a net margin of -44.64% compared to Oxford BioDynamics' net margin of -1,800.32%. Futura Medical's return on equity of -56.44% beat Oxford BioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Futura Medical	-44.64%	-56.44%	-26.59%
Oxford BioDynamics	-1,800.32%	-289.38%	-56.23%

Do insiders & institutionals believe in FUM or OBD?

35.7% of Futura Medical shares are held by institutional investors. Comparatively, 44.3% of Oxford BioDynamics shares are held by institutional investors. 32.1% of Futura Medical shares are held by company insiders. Comparatively, 16.8% of Oxford BioDynamics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Does the media refer more to FUM or OBD?

In the previous week, Oxford BioDynamics had 1 more articles in the media than Futura Medical. MarketBeat recorded 1 mentions for Oxford BioDynamics and 0 mentions for Futura Medical. Futura Medical's average media sentiment score of 0.00 beat Oxford BioDynamics' score of -0.95 indicating that Futura Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Futura Medical	Neutral
Oxford BioDynamics	Negative

Which has more risk & volatility, FUM or OBD?

Futura Medical has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Oxford BioDynamics has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.

Which has higher valuation and earnings, FUM or OBD?

Futura Medical has higher revenue and earnings than Oxford BioDynamics. Futura Medical is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Futura Medical	£8.68M	2.58	-£3.88M	-£1.21	-5.94
Oxford BioDynamics	£5.75M	0.98	-£103.52M	-£5.70	-0.05

Summary

Futura Medical beats Oxford BioDynamics on 10 of the 13 factors compared between the two stocks.